- Home
- RLAY vs BTO Comparison
RLAY vs BTO Comparison
Compare RLAY & BTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLAY
- BTO
- Stock Information
- Founded
- RLAY 2015
- BTO 1994
- Country
- RLAY United States
- BTO United States
- Employees
- RLAY N/A
- BTO N/A
- Industry
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- BTO Investment Managers
- Sector
- RLAY Health Care
- BTO Finance
- Exchange
- RLAY Nasdaq
- BTO Nasdaq
- Market Cap
- RLAY 1.0B
- BTO 726.7M
- IPO Year
- RLAY 2020
- BTO N/A
- Fundamental
- Price
- RLAY $6.15
- BTO $33.51
- Analyst Decision
- RLAY Strong Buy
- BTO
- Analyst Count
- RLAY 9
- BTO 0
- Target Price
- RLAY $16.00
- BTO N/A
- AVG Volume (30 Days)
- RLAY 2.2M
- BTO 54.2K
- Earning Date
- RLAY 11-06-2025
- BTO 01-01-0001
- Dividend Yield
- RLAY N/A
- BTO 9.13%
- EPS Growth
- RLAY N/A
- BTO N/A
- EPS
- RLAY N/A
- BTO N/A
- Revenue
- RLAY $8,355,000.00
- BTO N/A
- Revenue This Year
- RLAY $27.30
- BTO N/A
- Revenue Next Year
- RLAY $7.43
- BTO N/A
- P/E Ratio
- RLAY N/A
- BTO N/A
- Revenue Growth
- RLAY N/A
- BTO N/A
- 52 Week Low
- RLAY $1.78
- BTO $22.95
- 52 Week High
- RLAY $7.64
- BTO $32.81
- Technical
- Relative Strength Index (RSI)
- RLAY 45.56
- BTO 42.56
- Support Level
- RLAY $6.64
- BTO $32.20
- Resistance Level
- RLAY $7.42
- BTO $33.72
- Average True Range (ATR)
- RLAY 0.44
- BTO 0.79
- MACD
- RLAY -0.19
- BTO -0.02
- Stochastic Oscillator
- RLAY 8.31
- BTO 45.96
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
About BTO John Hancock Financial Opportunities Fund
John Hancock Financial Opportunities Fund is the United States based closed-end, diversified management investment company. Its investment objective is to provide a high level of total return consisting of long-term capital appreciation and current income. The company invests in banks, capital markets, Insurance, Mortage Real Estate Investment trust, Health Care REITs, Diversified REITs, Office REITs.